Contrast-enhanced ultrasound of renal masses.
renal cell carcinoma; biopsy; Contrast enhanced ultrasound; angiomyolipoma; onocytoma; sonovue
Contrast enhanced ultrasound (CEUS) has gained clinical importance over the last years for the characterization of hepatic masses. Its role in extrahepatic indications has been investigated repeatedly but has been less comprehensively studied. Currently more than 50% of renal masses are incidentally diagnosed, mostly by B-mode ultrasound. The method of choice for characterization of renal lesions is contrast enhanced computed tomography (CECT). In the case of cystic lesions CECT refers to the Bosniak classification for cystic lesions to assess the risk of malignant behavior. The majority of masses are renal cell carcinoma, but the exact proportion is controversial. Disadvantages of CECT are a significant risk for patients with impaired renal function, allergic reactions and hyperthyroidism due to iodinated contrast agents. Several studies concerning CEUS for the characterization of both solid and cystic renal lesions have been published, but prospective multicenter studies are missing, the presented data being mainly descriptive. The aim of the this manuscript is to review the current literature for CEUS in renal masses, to summarize the available data and focus on possible concepts for studies in the future.
Bennett J;Peterson C;Barr RG
Applied Radiology
2020
2020-12-11
journalArticle
<a href="http://doi.org/" target="_blank" rel="noreferrer noopener"></a>
Contrast enhanced ultrasound for focal liver lesions: how accurate is it?
diagnosis; ultrasonography; Radiology; metaanalysis; Nuclear Medicine & Medical Imaging; ct; us; hepatocellular carcinoma; benign; ceus; Contrast enhanced ultrasound; Focal liver lesions; mri; Sensitivity; washout
With the recent FDA approval for characterization of focal liver lesions (FLL) in both pediatric and adult patients using Lumason (sulfur hexafluoride microbubbles), increased use of ultrasound contrast for routine clinical use is expected. This agent has been available for many years in Europe and Asia, and a large body of literature is available regarding the sensitivity and specificity of this agent. In addition, a few studies have directly compared CEUS to CECT and CEMRI for the characterization of focal liver lesions. This paper reviews the literature to provide a background to investigators in the United States as to the accuracy of CEUS in the characterization of FLL. This paper reviews the literature regarding sulfur hexafluoride microbubbles (Lumason in the USA and Sonovue in the rest of the world) since it is the only FDA approved agent in the USA for characterization of FLL. The results of other ultrasound contrast agents which are not FDA approved for abdominal indications (approval for cardiac indications) most likely will have similar results.
Barr R G
Abdominal Radiology
2018
2018-05
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1007/s00261-017-1257-6" target="_blank" rel="noreferrer noopener">10.1007/s00261-017-1257-6</a>